Paget's disease of bone: Clinical review and update

Journal of Clinical Pathology

Volumn 66, Issue 11, 2013, Pages 924-927

  Bolland, Mark J ^a   Cundy, Tim ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ANALGESIC AGENT; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; DEOXPYRIDINOLINE; ETIDRONIC ACID; IBANDRONIC ACID; OSTEOCALCIN; PLACEBO; PROCOLLAGEN TYPE I N TERMINAL PROPEPTIDE; RISEDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ARTICLE; BONE BIOPSY; BONE MALFORMATION; BONE PAIN; BONE REMODELING; BONE SCINTISCANNING; BONE TURNOVER; CLINICAL FEATURE; DISEASE SEVERITY; DRUG POTENCY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENOTYPE PHENOTYPE CORRELATION; HEREDITY; HIGH OUTPUT HEART FAILURE; HUMAN; INCIDENCE; KINESIOTHERAPY; MEDICATION THERAPY MANAGEMENT; NONHUMAN; OSSIFICATION; OSTEOARTHRITIS; OSTEOCLAST ACTIVITY; OSTEOLYSIS; OSTEOSARCOMA; OSTEOSCLEROSIS; PAGET BONE DISEASE; PATHOLOGIC FRACTURE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; SQSTM1 GENE; TREATMENT DURATION; VERTEBRAL CANAL STENOSIS; WEIGHT REDUCTION;

BONE; ENDOCRINOLOGY; PAGET'S DISEASE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; BONE AND BONES; DIPHOSPHONATES; ENVIRONMENT; GENOTYPE; HUMANS; INCIDENCE; MUTATION; OSTEITIS DEFORMANS; PHENOTYPE; PREVALENCE; REMISSION INDUCTION;

EID: 84888297148     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201688     Document Type: Article

References (49)

1. Corral-Gudino L, Borao-Cengotita-Bengoa M, Del Pino-Montes J, et al. Epidemiology of Paget's disease of bone: a systematic review and meta-analysis of secular changes. Bone 2013;55:347-52.
2. Ralston SH. Clinical practice. Paget's disease of bone. N Engl J Med 2013;368:644-50.
3. Sankaran S, Naot D, Grey A, et al. Paget's disease in patients of Asian descent in New Zealand. J Bone Miner Res 2012;27:223-6.
4. Barker DJ, Chamberlain AT, Guyer PB, et al. Paget's disease of bone: the Lancashire focus. Br Med J 1980;280:1105-7.
5. Gennari L, Merlotti D, Martini G, et al. Paget's disease of bone in Italy. J Bone Miner Res 2006;21(Suppl 2):P14-21.
6. Lopez-Abente G, Morales-Piga A, Bachiller-Corral FJ, et al. Identification of possible areas of high prevalence of Paget's disease of bone in Spain. Clin Exp Rheumatol 2003;21:635-8.
7. Doyle T, Gunn J, Anderson G, et al. Paget's disease in New Zealand: evidence for declining prevalence. Bone 2002;31:616-19.
8. Bastin S, Bird H, Gamble G, et al. Paget's disease of bone-becoming a rarity? Rheumatology (Oxford) 2009;48:1232 -5.
9. Tiegs RD, Lohse CM, Wollan PC, et al. Long-term trends in the incidence of Paget's disease of bone. Bone 2000;27:423-7.
10. van Staa TP, Selby P, Leufkens HG, et al. Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res 2002;17:465-71.
11. Cundy T, McAnulty K, Wattie D, et al. Evidence for secular change in Paget's disease. Bone 1997;20:69-71.
12. Morales-Piga AA, Bachiller-Corral FJ, Abraira V, et al. Is clinical expressiveness of Paget 's disease of bone decreasing? Bone 2002;30:399-403.
13. Cundy HR, Gamble G, Wattie D, et al. Paget's disease of bone in New Zealand: continued decline in disease severity. Calcif Tissue Int 2004;75:358-64.
14. Corral-Gudino L, Garcia-Aparicio J, Sanchez-Gonzalez MD, et al. Secular changes in Paget 's disease: contrasting changes in the number of new referrals and in disease severity in two neighboring regions of Spain. Osteoporos Int 2013;24:443-50.
15. Kanis JA. Pathophysiology and treatment of Pagets disease of bone. London: Martin Dunitz, 1998.
16. Cundy T, Bolland M. Paget disease of bone. Trends Endocrinol Metab 2008;19:246-53.
17. Naot D, Bava U, Matthews B, et al. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone. J Bone Miner Res 2007;22:298-309.
18. Morales-Piga AA, Rey-Rey JS, Corres-Gonzalez J, et al. Frequency and characteristics of familial aggregation of Paget's disease of bone. J Bone Miner Res 1995;10:663-70.
19. Hocking LJ, Lucas GJ, Daroszewska A, et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet 2002;11:2735-9.
20. Laurin N, Brown JP, Morissette J, et al. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 2002;70:1582-8.
21. Cavey JR, Ralston SH, Hocking LJ, et al. Loss of ubiquitin-binding associated with Paget's disease of bone p62 (SQSTM1) mutations. J Bone Miner Res 2005;20:619-24.
22. Hocking LJ, Lucas GJ, Daroszewska A, et al. Novel UBA domain mutations of SQSTM1 in Paget's disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. J Bone Miner Res 2004;19:1122-7.
23. Rea SL, Walsh JP, Ward L, et al. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype. J Bone Miner Res 2006;21:1136-45.
24. Bolland MJ, Tong PC, Naot D, et al. Delayed development of Paget's disease in offspring inheriting SQSTM1 mutations. J Bone Miner Res 2007;22:411-15.
25. Visconti MR, Langston AL, Alonso N, et al. Mutations of SQSTM1 are associated with severity and clinical outcome in Paget disease of bone. J Bone Miner Res 2010;25:2368-73.
26. Cundy T, Naot D, Bava U, et al . Familial Paget disease and SQSTM1 mutations in New Zealand. Calcif Tissue Int 2011;89:258-64.
27. Beyens G, Van Hul E, Van Driessche K, et al . Evaluation of the role of the SQSTM1 gene in sporadic Belgian patients with Paget's disease. Calcif Tissue Int 2004;75:144-52.
28. Falchetti A, Di Stefano M, Marini F, et al. Two novel mutations at exon 8 of the Sequestosome 1 (SQSTM1) gene in an Italian series of patients affected by Paget's disease of bone (PDB). J Bone Miner Res 2004;19:1013-17.
29. Laurin N, Brown JP, Lemainque A, et al. Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet 2001;69:528-43.
30. Albagha OM, Visconti MR, Alonso N, et al. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nat Genet 2010;42:520-4.
31. Albagha OM, Wani SE, Visconti MR, et al. Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. Nat Genet 2011;43:685-9.
32. Naot D. Paget's disease of bone: an update. Curr Opin Endocrinol Diabetes Obes 2011;18:352-8.
33. Mee AP. Paramyxoviruses and Paget's disease: the affirmative view. Bone 1999;24:19S-21S.
34. Friedrichs WE, Reddy SV, Singer FR, et al. The pro and con of measles virus in Paget's disease: Pro. J Bone Miner Res 2002;17:2293.
35. Roodman GD. Insights into the pathogenesis of Paget's disease. Ann N Y Acad Sci 2010;1192:176-80.
36. Kurihara N, Hiruma Y, Yamana K, et al. Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. Cell Metab 2011;13:23-34.
37. Ralston SH, Helfrich MH. Are paramyxoviruses involved in Paget's disease? A negative view. Bone 1999;24:17S-18S.
38. Rima BK. Paramyxoviruses and chronic human diseases. Bone 1999;24:23S-6S.
39. Rima BK, Gassen U, Helfrich MH, et al . The pro and con of measles virus in Paget's disease: con. J Bone Miner Res 2002;17:2290-2; author reply 93.
40. Helfrich MH, Hobson RP, Grabowski PS, et al. A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res 2000;15:2315-29.
41. Ralston SH, Afzal MA, Helfrich MH, et al. Multicenter blinded analysis of RT-PCR detection methods for paramyxoviruses in relation to Paget's disease of bone. J Bone Miner Res 2007;22:569-77.
42. Matthews BG, Afzal MA, Minor PD, et al. Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget's disease. J Clin Endocrinol Metab 2008;93:1398-401.
43. Holdaway IM, Ibbertson HK, Wattie D, et al. Previous pet ownership and Paget's disease. Bone Miner 1990;8:53-8.
44. Reid IR, Davidson JS, Wattie D, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 2004;35:224-30.
45. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005;353:898-908.
46. Hosking D, Lyles K, Brown JP, et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 2007;22:142-8.
47. Reid IR, Lyles K, Su G, et al. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res 2011;26:2261-70.
48. Langston AL, Campbell MK, Fraser WD, et al. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget' s disease of bone. J Bone Miner Res 2010;25:20-31.
49. Reid IR, Cundy T, Bolland MJ, et al. Response to publication of PRISM trial. J Bone Miner Res 2010;25:1463-4; author reply 65-6.